文献速递哮喘

新型数字化自动化自我管理方案对未控制哮喘的临床效果:一项医师盲法随机交叉试验

Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial.
PubMed 文献 · Eur Respir J · 2019-11-14

该多中心医师盲法随机交叉试验纳入77例未控制哮喘患者,比较AsthmaTuner数字化自我管理方案与常规治疗各8周的效果。结果显示AsthmaTuner组ACT评分显著改善(平均差0.70,95%CI 0.06-1.34;p=0.03),但全体患者依从性未显著改善,仅在每周使用≥1次的基层医疗患者中MARS评分改善(平均差0.45,95%CI 0.13-0.77;p=0.01)。

要点

  • AsthmaTuner可显著改善未控制哮喘患者的症状控制(ACT平均差0.70)。
  • 全体患者用药依从性未显著改善。
  • 基层医疗中每周使用≥1次者依从性显著改善(MARS平均差0.45)。

核心结论

  • AsthmaTuner数字化自我管理方案较常规治疗可改善未控制哮喘患者的症状控制。

研究设计与样本

  • 多中心医师盲法随机交叉试验,纳入瑞典初级或儿科医疗环境中确诊哮喘、症状未控制且ACT评分<20分的患者。
  • 共77例患者(60%为女性),随机分两组,先后接受8周AsthmaTuner或常规治疗(个性化打印治疗计划),交叉之间设2周洗脱期。

主要发现

  • AsthmaTuner组较常规治疗组ACT评分显著改善,平均ACT差值为0.70(95%CI 0.06-1.34;p=0.03)。
  • 全体参与者用药依从性(MARS评分)未显著改善。
  • 基层医疗中每周使用AsthmaTuner≥1次的患者较常规治疗MARS评分显著改善,平均差值为0.45(95%CI 0.13-0.77;p=0.01)。

临床怎么用

  • 对于未控制哮喘患者,可考虑使用AsthmaTuner数字化自我管理方案以改善症状控制。
  • 在基层医疗中,鼓励患者每周至少使用一次该方案可能有助于改善用药依从性。

局限性

  • 本研究为试点研究,样本量有限(77例)。
  • 依从性改善仅在基层医疗高频使用亚组中显著,全体患者未达显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: AsthmaTuner is a novel self-management system consisting of a patient app, a cloud-based storage solution and a healthcare interface. Patients use Bluetooth spirometers to measure lung function (forced expiratory volume in 1 s) and can register symptoms. They then receive immediate feedback on asthma control and an image of the correct inhaler(s) to use and the dose. The aim of this pilot study was to evaluate the effect of AsthmaTuner on symptom control and adherence compared with conventional treatment. MATERIAL AND METHODS: This multicentre physician-blinded crossover trial randomised patients in two groups that started with 8 weeks of AsthmaTuner or conventional treatment using a personalised printed treatment plan, with 2 weeks of washout between the crossover treatments. Participants in a primary or paediatric care setting in Sweden with asthma diagnosis, uncontrolled symptoms and Asthma Control Test (ACT) score <20 points were included. Symptom control was analysed using t-tests for the difference between the group means of the sums of ACT scores at each treatment end-visit, with 95% confidence intervals. Medical Adherence Report Scale (MARS) scores captured differences in adherence (remembering to take asthma medication) between treatment periods. RESULTS: The study population consisted of 77 patients (60% females). The ACT score significantly improved with AsthmaTuner compared with conventional treatment (mean ACT difference 0.70, 95% CI 0.06-1.34; p=0.03). Adherence did not improve significantly in all participants, but did improve among those in primary care who used AsthmaTuner an average of once a week or more compared with conventional treatment (mean MARS difference 0.45, 95% CI 0.13-0.77; p=0.01). CONCLUSIONS: AsthmaTuner improved symptom control in patients with uncontrolled asthma compared with conventional treatment.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Ljungberg H, Carleborg A, Gerber H, et al. Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial. Eur Respir J. 2019. PMID: 31481605. doi:10.1183/13993003.00983-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。